Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study


Kohli P., Wallentin L., Reyes E., Horrow J., Husted S., Angiolillo D. J. , ...Daha Fazla

CIRCULATION, cilt.127, ss.673-681, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Background-We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (eg, cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events.